Antares Pharma (NASDAQ:ATRS) Downgraded by ValuEngine
Separately, BidaskClub raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $4.05.
NASDAQ ATRS opened at $4.95 on Tuesday. Antares Pharma has a 52 week low of $2.53 and a 52 week high of $5.06. The company has a quick ratio of 2.46, a current ratio of 2.95 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $772.06 million, a P/E ratio of -123.75 and a beta of 0.91. The stock’s 50-day moving average price is $3.93 and its 200-day moving average price is $3.36.
A number of institutional investors have recently modified their holdings of the stock. Bank of Montreal Can bought a new position in Antares Pharma in the 2nd quarter worth approximately $45,000. Aperio Group LLC bought a new stake in shares of Antares Pharma during the second quarter valued at approximately $47,000. Millennium Management LLC bought a new stake in shares of Antares Pharma during the third quarter valued at approximately $48,000. Alpine Woods Capital Investors LLC lifted its holdings in shares of Antares Pharma by 60.0% in the second quarter. Alpine Woods Capital Investors LLC now owns 16,000 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 6,000 shares in the last quarter. Finally, Prudential Financial Inc. lifted its holdings in shares of Antares Pharma by 33.8% in the second quarter. Prudential Financial Inc. now owns 18,530 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 4,680 shares in the last quarter. 38.62% of the stock is owned by institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Story: Market Perform
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.